28125612|t|A Recombinant Human Anti-Platelet scFv Antibody Produced in Pichia pastoris for Atheroma Targeting
28125612|a|Cells of the innate and adaptive immune system are key factors in the progression of atherosclerotic plaque, leading to plaque instability and rupture, potentially resulting in acute atherothrombotic events such as coronary artery disease, cerebrovascular disease and peripheral arterial disease. Here, we describe the cloning, expression, purification, and immunoreactivity assessment of a recombinant single-chain variable fragment (scFv) derived from a human anti-αIIbβ3 antibody (HuAb) selected to target atheromatous lesions for the presence of platelets. Indeed, platelets within atheroma plaques have been shown to play a role in inflammation, in platelet - leucocyte aggregates and in thrombi formation and might thus be considered relevant biomarkers of atherosclerotic progression. The DNA sequence that encodes the anti-αIIbβ3 TEG4 scFv previously obtained from a phage-display selection on activated platelets, was inserted into the eukaryote vector (pPICZαA) in fusion with a tag sequence encoding 2 cysteines useable for specific probes grafting experiments. The recombinant protein was expressed at high yields in Pichia pastoris (30 mg/L culture). The advantage of P. pastoris as an expression system is the production and secretion of recombinant proteins in the supernatant, ruling out the difficulties encountered when scFv are produced in the cytoplasm of bacteria (low yield, low solubility and reduced affinity). The improved conditions allowed for the recovery of highly purified and biologically active scFv fragments ready to be grafted in a site -directed way to nanoparticles for the imaging of atherosclerotic plaques involving inflammatory processes and thus at high risk of instability.
28125612	2	13	Recombinant	T063	C0017387
28125612	14	19	Human	T016	C0086418
28125612	20	47	Anti-Platelet scFv Antibody	T116,T129	C0370058
28125612	34	38	scFv	T129	C1883036
28125612	60	75	Pichia pastoris	T004	C0997362
28125612	80	88	Atheroma	T046	C0264956
28125612	99	104	Cells	T025	C0007634
28125612	132	145	immune system	T022	C0020962
28125612	169	180	progression	T046	C0242656
28125612	184	206	atherosclerotic plaque	T031	C2936350
28125612	219	225	plaque	T033	C0332461
28125612	226	237	instability	T033	C1444783
28125612	242	249	rupture	T037	C3203359
28125612	276	281	acute	T079	C0205178
28125612	282	298	atherothrombotic	T020	C1963943
28125612	314	337	coronary artery disease	T047	C0010054
28125612	339	362	cerebrovascular disease	T047	C0007820
28125612	367	394	peripheral arterial disease	T047	C0085096
28125612	418	425	cloning	T062	C0525050
28125612	427	437	expression	T045	C1171362
28125612	439	451	purification	T169	C1998793
28125612	457	473	immunoreactivity	T044	C0597879
28125612	474	484	assessment	T058	C0220825
28125612	490	501	recombinant	T001	C1514798
28125612	502	532	single-chain variable fragment	T129	C1883036
28125612	534	538	scFv	T129	C1883036
28125612	555	560	human	T016	C0086418
28125612	561	581	anti-αIIbβ3 antibody	T116,T129,T192	C0016011
28125612	583	587	HuAb	T116,T129,T192	C0016011
28125612	608	620	atheromatous	T046	C0264956
28125612	621	628	lesions	T033	C0221198
28125612	637	645	presence	T033	C0150312
28125612	649	658	platelets	T025	C0005821
28125612	668	677	platelets	T025	C0005821
28125612	685	701	atheroma plaques	T031	C2936350
28125612	736	748	inflammation	T046	C0021368
28125612	753	761	platelet	T025	C0005821
28125612	764	773	leucocyte	T025	C0023516
28125612	774	784	aggregates	T080	C0205418
28125612	792	799	thrombi	T046	C0087086
28125612	800	809	formation	T169	C1522492
28125612	839	847	relevant	T080	C2347946
28125612	848	858	biomarkers	T201	C0005516
28125612	862	877	atherosclerotic	T169	C0333482
28125612	878	889	progression	T046	C0242656
28125612	895	907	DNA sequence	T086	C0162326
28125612	913	920	encodes	T052	C2700640
28125612	925	946	anti-αIIbβ3 TEG4 scFv	T129	C1883036
28125612	974	997	phage-display selection	T063	C3494191
28125612	1001	1010	activated	T052	C1879547
28125612	1011	1020	platelets	T025	C0005821
28125612	1026	1034	inserted	T045	C1512796
28125612	1044	1053	eukaryote	T204	C0684063
28125612	1054	1060	vector	T114	C1514152
28125612	1062	1069	pPICZαA	T114	C1514152
28125612	1088	1100	tag sequence	T086	C0162326
28125612	1101	1109	encoding	T052	C2700640
28125612	1112	1121	cysteines	T116,T123	C0010654
28125612	1134	1142	specific	T080	C0205369
28125612	1150	1170	grafting experiments	T059	C0022885
28125612	1176	1195	recombinant protein	T116	C0034861
28125612	1200	1209	expressed	T045	C1171362
28125612	1213	1217	high	T080	C0205250
28125612	1228	1243	Pichia pastoris	T004	C0997362
28125612	1253	1260	culture	T130	C0010454
28125612	1280	1291	P. pastoris	T004	C0997362
28125612	1298	1308	expression	T045	C1171362
28125612	1309	1315	system	T169	C0449913
28125612	1338	1347	secretion	T038	C0036536
28125612	1351	1371	recombinant proteins	T116	C0034861
28125612	1379	1390	supernatant	T031	C1550101
28125612	1437	1441	scFv	T129	C1883036
28125612	1462	1471	cytoplasm	T026	C0010834
28125612	1475	1483	bacteria	T007	C0004611
28125612	1485	1488	low	T080	C0205251
28125612	1489	1494	yield	T081	C0392762
28125612	1496	1499	low	T080	C0205251
28125612	1500	1510	solubility	T080	C0037628
28125612	1515	1522	reduced	T080	C0392756
28125612	1523	1531	affinity	T044	C0003255
28125612	1538	1546	improved	T033	C0184511
28125612	1574	1582	recovery	T052	C0237820
28125612	1586	1592	highly	T080	C0205250
28125612	1593	1601	purified	T169	C1998793
28125612	1606	1640	biologically active scFv fragments	T123	C0574031
28125612	1626	1630	scFv	T129	C1883036
28125612	1653	1660	grafted	T169	C0700106
28125612	1666	1670	site	T082	C0205145
28125612	1688	1701	nanoparticles	T073	C1450054
28125612	1710	1717	imaging	T060	C0011923
28125612	1721	1744	atherosclerotic plaques	T031	C2936350
28125612	1755	1767	inflammatory	T169	C0333348
28125612	1768	1777	processes	T067	C1522240
28125612	1790	1802	high risk of	T033	C0332167
28125612	1803	1814	instability	T033	C1444783